Valrubicin
From Wikipedia, the free encyclopedia
|
Valrubicin
|
|
| Systematic (IUPAC) name | |
| [2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate | |
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C34H36F3NO13 |
| Mol. mass | 723.644 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | >99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
[edit] Dosage
800 mg weekly for 6 weeks
[edit] Side effects
- Blood in urine
- Incontinence
- painful or difficult urination
- Unusually frequent urination

